Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats

Arthur L Swislocki, T. L. Kinney Lapier, D. T. Khuu, K. Y. Fann, M. Tait, K. J. Rodnick

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Spontaneously hypertensive rats (SHR) demonstrate elevated blood pressure, cardiac hypertrophy, glucose intolerance, and insulin resistance compared with age-matched Wistar-Kyoto rats (WKY). We investigated concurrent effects of captopril on blood pressure, cardiac mass, myocardial enzyme activities, glucose tolerance, and insulin action in young male SHR. At 10 weeks of age, SHR were randomized into two groups, one receiving distilled water, the other a captopril solution (50 mg/kg body weight/day). We also examined age-matched WKY receiving distilled water. Blood pressure was measured by tail-cuff during the 4-week treatment period and oral glucose tolerance was tested at the end of treatment. Hearts were weighed and ventricular tissue was assayed for activities of 3-hydroxyacyl-CoA dehydrogenase, citrate synthase, and hexokinase. Growth rates were similar between captopril-treated and control SHR, but less than those of WKY. Captopril reduced blood pressure (134 ± 8 v 177 ± 8 mm Hg, P < .05) and left ventricular mass (-18%, P < .05) in SHR. Cardiac enzyme activities also changed with captopril treatment, reflecting an increased capacity for β- oxidation of fatty acids and reduced potential for glucose phosphorylation in the left ventricle of SHR. Serum concentrations of glucose, insulin, and free fatty acids after a brief fast and in response to oral glucose were not different after captopril treatment, suggesting no improvement in insulin action or glucose tolerance. In summary, treatment of young male SHR with captopril reduces blood pressure and cardiac mass, and promotes a small but significant increase in cardiac capacity for oxidation of fatty acids and reduction of glucose phosphorylation. In contrast, metabolic effects of captopril on oral glucose tolerance and insulin action were not evident.

Original languageEnglish (US)
Pages (from-to)581-589
Number of pages9
JournalAmerican Journal of Hypertension
Volume12
Issue number6
DOIs
StatePublished - Jun 1999

Fingerprint

Captopril
Inbred SHR Rats
Hemodynamics
Glucose
Inbred WKY Rats
Blood Pressure
Insulin
Glucose Tolerance Test
Fatty Acids
3-Hydroxyacyl-CoA Dehydrogenase
Phosphorylation
Citrate (si)-Synthase
Hexokinase
Glucose Intolerance
Water
Cardiomegaly
Enzymes
Nonesterified Fatty Acids
Heart Ventricles
Insulin Resistance

Keywords

  • Captopril
  • Cardiac metabolism
  • Glucose tolerance
  • Insulin action
  • Spontaneously hypertensive rat

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats. / Swislocki, Arthur L; Kinney Lapier, T. L.; Khuu, D. T.; Fann, K. Y.; Tait, M.; Rodnick, K. J.

In: American Journal of Hypertension, Vol. 12, No. 6, 06.1999, p. 581-589.

Research output: Contribution to journalArticle

Swislocki, Arthur L ; Kinney Lapier, T. L. ; Khuu, D. T. ; Fann, K. Y. ; Tait, M. ; Rodnick, K. J. / Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats. In: American Journal of Hypertension. 1999 ; Vol. 12, No. 6. pp. 581-589.
@article{ad235daf80a242bdb3815fd73cefee87,
title = "Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats",
abstract = "Spontaneously hypertensive rats (SHR) demonstrate elevated blood pressure, cardiac hypertrophy, glucose intolerance, and insulin resistance compared with age-matched Wistar-Kyoto rats (WKY). We investigated concurrent effects of captopril on blood pressure, cardiac mass, myocardial enzyme activities, glucose tolerance, and insulin action in young male SHR. At 10 weeks of age, SHR were randomized into two groups, one receiving distilled water, the other a captopril solution (50 mg/kg body weight/day). We also examined age-matched WKY receiving distilled water. Blood pressure was measured by tail-cuff during the 4-week treatment period and oral glucose tolerance was tested at the end of treatment. Hearts were weighed and ventricular tissue was assayed for activities of 3-hydroxyacyl-CoA dehydrogenase, citrate synthase, and hexokinase. Growth rates were similar between captopril-treated and control SHR, but less than those of WKY. Captopril reduced blood pressure (134 ± 8 v 177 ± 8 mm Hg, P < .05) and left ventricular mass (-18{\%}, P < .05) in SHR. Cardiac enzyme activities also changed with captopril treatment, reflecting an increased capacity for β- oxidation of fatty acids and reduced potential for glucose phosphorylation in the left ventricle of SHR. Serum concentrations of glucose, insulin, and free fatty acids after a brief fast and in response to oral glucose were not different after captopril treatment, suggesting no improvement in insulin action or glucose tolerance. In summary, treatment of young male SHR with captopril reduces blood pressure and cardiac mass, and promotes a small but significant increase in cardiac capacity for oxidation of fatty acids and reduction of glucose phosphorylation. In contrast, metabolic effects of captopril on oral glucose tolerance and insulin action were not evident.",
keywords = "Captopril, Cardiac metabolism, Glucose tolerance, Insulin action, Spontaneously hypertensive rat",
author = "Swislocki, {Arthur L} and {Kinney Lapier}, {T. L.} and Khuu, {D. T.} and Fann, {K. Y.} and M. Tait and Rodnick, {K. J.}",
year = "1999",
month = "6",
doi = "10.1016/S0895-7061(99)00012-6",
language = "English (US)",
volume = "12",
pages = "581--589",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats

AU - Swislocki, Arthur L

AU - Kinney Lapier, T. L.

AU - Khuu, D. T.

AU - Fann, K. Y.

AU - Tait, M.

AU - Rodnick, K. J.

PY - 1999/6

Y1 - 1999/6

N2 - Spontaneously hypertensive rats (SHR) demonstrate elevated blood pressure, cardiac hypertrophy, glucose intolerance, and insulin resistance compared with age-matched Wistar-Kyoto rats (WKY). We investigated concurrent effects of captopril on blood pressure, cardiac mass, myocardial enzyme activities, glucose tolerance, and insulin action in young male SHR. At 10 weeks of age, SHR were randomized into two groups, one receiving distilled water, the other a captopril solution (50 mg/kg body weight/day). We also examined age-matched WKY receiving distilled water. Blood pressure was measured by tail-cuff during the 4-week treatment period and oral glucose tolerance was tested at the end of treatment. Hearts were weighed and ventricular tissue was assayed for activities of 3-hydroxyacyl-CoA dehydrogenase, citrate synthase, and hexokinase. Growth rates were similar between captopril-treated and control SHR, but less than those of WKY. Captopril reduced blood pressure (134 ± 8 v 177 ± 8 mm Hg, P < .05) and left ventricular mass (-18%, P < .05) in SHR. Cardiac enzyme activities also changed with captopril treatment, reflecting an increased capacity for β- oxidation of fatty acids and reduced potential for glucose phosphorylation in the left ventricle of SHR. Serum concentrations of glucose, insulin, and free fatty acids after a brief fast and in response to oral glucose were not different after captopril treatment, suggesting no improvement in insulin action or glucose tolerance. In summary, treatment of young male SHR with captopril reduces blood pressure and cardiac mass, and promotes a small but significant increase in cardiac capacity for oxidation of fatty acids and reduction of glucose phosphorylation. In contrast, metabolic effects of captopril on oral glucose tolerance and insulin action were not evident.

AB - Spontaneously hypertensive rats (SHR) demonstrate elevated blood pressure, cardiac hypertrophy, glucose intolerance, and insulin resistance compared with age-matched Wistar-Kyoto rats (WKY). We investigated concurrent effects of captopril on blood pressure, cardiac mass, myocardial enzyme activities, glucose tolerance, and insulin action in young male SHR. At 10 weeks of age, SHR were randomized into two groups, one receiving distilled water, the other a captopril solution (50 mg/kg body weight/day). We also examined age-matched WKY receiving distilled water. Blood pressure was measured by tail-cuff during the 4-week treatment period and oral glucose tolerance was tested at the end of treatment. Hearts were weighed and ventricular tissue was assayed for activities of 3-hydroxyacyl-CoA dehydrogenase, citrate synthase, and hexokinase. Growth rates were similar between captopril-treated and control SHR, but less than those of WKY. Captopril reduced blood pressure (134 ± 8 v 177 ± 8 mm Hg, P < .05) and left ventricular mass (-18%, P < .05) in SHR. Cardiac enzyme activities also changed with captopril treatment, reflecting an increased capacity for β- oxidation of fatty acids and reduced potential for glucose phosphorylation in the left ventricle of SHR. Serum concentrations of glucose, insulin, and free fatty acids after a brief fast and in response to oral glucose were not different after captopril treatment, suggesting no improvement in insulin action or glucose tolerance. In summary, treatment of young male SHR with captopril reduces blood pressure and cardiac mass, and promotes a small but significant increase in cardiac capacity for oxidation of fatty acids and reduction of glucose phosphorylation. In contrast, metabolic effects of captopril on oral glucose tolerance and insulin action were not evident.

KW - Captopril

KW - Cardiac metabolism

KW - Glucose tolerance

KW - Insulin action

KW - Spontaneously hypertensive rat

UR - http://www.scopus.com/inward/record.url?scp=0344731322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344731322&partnerID=8YFLogxK

U2 - 10.1016/S0895-7061(99)00012-6

DO - 10.1016/S0895-7061(99)00012-6

M3 - Article

VL - 12

SP - 581

EP - 589

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 6

ER -